Takeoka T, Nagase H, Kurose K, Ohue Y, Yamasaki M, Takiguchi S, Sato E, Isobe M, Kanazawa T, Matsumoto M, et al. NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC. Journal of immunotherapy. 2017. Epub ahead of print
Shoko Kodama, Koji Kurose, Tomoyuki Mukai, Yoshitaka Morita. Nivolumab-induced polyarthritis. BMJ Case Reports. 2017. 2017
Yoshihiro Ohue, Koji Kurose, Ryohei Nozawa, Midori Isobe, Yumi Nishio, Tomonori Tanaka, Yoshinori Doki, Takashi Hori, Junya Fukuoka, Mikio Oka, et al. Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells. CANCER IMMUNOLOGY RESEARCH. 2016. 4. 12. 1049-1060
Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients
(第74回日本癌学会学術総会 2015)
Immunotherapy for solid tumors based on regulation of regulatory T lymphocyte
(第74回日本癌学会学術総会 2015)
Augmentation of anti-tumor immune responses by N-propionyl cysteaminylphenol-maleimid-dextran(NPCMD)
(第74回日本癌学会学術総会 2015)
Survival prediciting discriminant function with immune parameters for lung adenocarcinoma patients
(第74回日本癌学会学術総会 2015)
Discriminant function for predicting survival of lung adenocarcinoma patients developed by using immune parameters of PD-L1,Gal-9, and XAGE1 expression on tumor cells and T cell infiltration score.
(The Inaugural International Cancer Immunotherapy Conference 2015)